• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Curr Mol Med . NPC1 as a Modulator of Disease Severity and Viral Entry of Sars-CoV-2

tetano

Editor, Senior Moderator
Curr Mol Med


. 2020 Jul 13.
doi: 10.2174/1566524020666200713175426. Online ahead of print.
NPC1 as a Modulator of Disease Severity and Viral Entry of Sars-CoV-2


Cecilia Vial[SUP] 1 [/SUP], Juan Francisco Calder?n[SUP] 1 [/SUP], Andr?s D Klein[SUP] 1 [/SUP]



Affiliations

Abstract

The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1, MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endolysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.

Keywords: COVID-19; Niemann-Pick C1; SARS-Cov-2; drug repurposing; infection.; modifier gene;
 
Back
Top